Welcome to LookChem.com Sign In|Join Free

CAS

  • or

226250-03-9

Post Buying Request

226250-03-9 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

226250-03-9 Usage

Class

Benzimidazoles

Physical state

White solid

Molecular weight

345.217 g/mol

Use in medicinal chemistry and pharmaceutical research

Building block for the synthesis of biologically active compounds

Use as an intermediate

Production of pharmaceuticals, agrochemicals, and other fine chemicals

Potential applications

Development of antiviral, antifungal, and anticancer drugs.

Check Digit Verification of cas no

The CAS Registry Mumber 226250-03-9 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 2,2,6,2,5 and 0 respectively; the second part has 2 digits, 0 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 226250-03:
(8*2)+(7*2)+(6*6)+(5*2)+(4*5)+(3*0)+(2*0)+(1*3)=99
99 % 10 = 9
So 226250-03-9 is a valid CAS Registry Number.

226250-03-9SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 20, 2017

Revision Date: Aug 20, 2017

1.Identification

1.1 GHS Product identifier

Product name 1-(tert-butoxycarbonyl)-6-(bromomethyl)benz[d]imidazole

1.2 Other means of identification

Product number -
Other names tert-Butyl 6-(bromomethyl)-1H-benzo[d]imidazole-1-carboxylate

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:226250-03-9 SDS

226250-03-9Downstream Products

226250-03-9Relevant articles and documents

SUBSTITUTED PYRIDINES AS INHIBITORS OF DNMT1

-

Page/Page column 1016-1017, (2018/01/20)

The invention is directed to substituted pyridine derivatives. Specifically, the invention is directed to compounds according to Formula (Iar): (Iar) wherein Yar, X1ar, X2ar, R1ar, R2ar, R3ar, R4ar and R5ar are as defined herein; or a pharmaceutically acceptable salt or prodrug thereof. The compounds of the invention are selective inhibitors of DNMT1 and can be useful in the treatment of cancer, pre-cancerous syndromes, beta hemoglobinopathy disorders, sickle cell disease, sickle cell anemia, and beta thalassemia, and diseases associated with DNMT1 inhibition. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting DNMT1 activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

TETRACYCLIC INDOLE DERIVATIVES AND METHODS OF USE THEREOF

-

Page/Page column 157; 164, (2009/04/25)

The present invention relates to Tetracyclic Indole Derivatives, compositions comprising at least one Tetracyclic Indole Derivative, and methods of using the Tetracyclic Indole Derivatives for treating or preventing a viral infection or a virus-related disorder in a patient.

SUBSTITUTED INDOLE DERIVATIVES AND METHODS OF USE THEREOF

-

Page/Page column 197-198; 205-206, (2009/04/25)

The present invention relates to Substituted Indole Derivatives, compositions comprising at least one Substituted Indole Derivative, and methods of using these Substituted Indole Derivatives for treating or preventing a viral infection or a virus-related disorder in a patient.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 226250-03-9